Identification of PANoptosis-related hub genes in acute myocardial infarction: diagnostic potential, immune correlates, and therapeutic insights Authors: Xuebing Wang, Xunli Yin, Linlin Teng, Dong Tao Published: 2026 ABSTRACT BackgroundPANoptosis is an innate immune-inflammatory programmed cell death pathway that integrates the key features of apoptosis, pyroptosis, and necroptosis. However, the diagnostic potential and immune relevance of PANoptosis-related genes in acute myocardial infarction (AMI) remain unclear.MethodsTranscriptional data were obtained from the GEO database, including the training set GSE66360 and validation set GSE59867. Differential expression, protein-protein interaction networks, and random forest analyses were conducted to identify PANoptosis-related hub genes associated with AMI pathogenesis. The diagnostic model and nomogram were built, and the diagnostic value was evaluated using receiver operating characteristic analysis. Immune infiltration, functional enrichment, and regulatory network analyses were performed to explore potential molecular mechanisms. Blood samples from healthy controls and AMI patients were collected to validate the expression of hub genes.ResultsA total of 438 DEGs and 109 PANoptosis-related genes were obtained. After intersecting these, 8 PANoptosis genes associated with AMI were found, enriched in apoptosis, immune, and inflammatory pathways. Two hub genes, IL1B and NLRP3, were identified as hub genes, with diagnostic models and nomograms showing good performance in both training and validation sets. These genes were significantly correlated with most immune cells that were dysregulated in AMI, revealing their immunomodulatory function. CEBPB and SPI1 were identified as common transcriptional regulators of the hub genes. Five drugs associated with hub genes were predicted from the DSigDB database. IL1B and NLRP3 showed consistent expression patterns across the training set, validation set, and real-time qPCR analysis.ConclusionIL1B and NLRP3 may serve as PANoptosis-related biomarkers with potential immunomodulation in AMI, offering preliminary insights into the potential molecular mechanisms of PANoptosis in AMI.Trial registrationNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13019-026-04421-1. Introduction Cardiovascular diseases (CVDs) are the leading cause of death worldwide, and acute myocardial infarction (AMI) is one of the most serious and common acute events in CVD [1]. Timely diagnosis and risk stratification are crucial for effective treatment and improving prognosis [2]. Clinical features, electrocardiograms (ECG), and biomarkers of cardiomyocyte damage are commonly used for AMI diagnosis, but their sensitivity remains inadequate [2, 3]. High-sensitivity cardiac troponin (hs-cTn), the preferred biomarker for AMI, suffers from false positives in certain patient populations, such as elderly individuals or those with chronic kidney disease, reducing its specificity [4–6]. Therefore, new biomarkers are needed to enhance AMI diagnosis. AMI is often caused by atherosclerotic plaque rupture, leading to hypoxic cardiomyocyte injury and necrosis [7]. Inflammation and immune modulation play key and dual roles in AMI progression [8, 9]. During the early stages, inflammation exacerbates myocardial injury and enlarges the infarct area, whereas in the repair phase, immune cells clear necrotic debris, aiding tissue repair and remodeling [10, 11]. Cell death mechanisms also significantly contribute to AMI and interact with the immune response [12]. Apoptosis, a controlled form of programmed cell death (PCD), eliminates damaged cells and regulates tissue homeostasis. In AMI, deleting apoptosis inhibitor of macrophage (AIM) has been shown to reduce infarct size and inflammation, improving ventricular remodeling [13]. Pyroptosis, an inflammatory form of PCD, is characterized by the release of pro-inflammatory cytokines and cell lysis [14], and its inhibition in AMI models reduces cardiomyocyte injury and inflammation [15]. Necroptosis, a caspase-independent PCD form, triggers cell rupture and inflammation through the release of damage-associated molecular patterns (DAMPs) [16]. Targeting necroptosis-related proteins or pathways has shown potential in mitigating ischemic myocardial injury [17]. Understanding the molecular mechanisms of PCD and its interaction with the immune system in AMI is crucial for improving patient outcomes and therapies. PANoptosis is a distinct PCD pathway that integrates features of pyroptosis, apoptosis, and necroptosis, acting as an innate immunoinflammatory response regulator through DAMPs and pro-inflammatory cytokines [18, 19]. Evidence suggests that PANoptosis is involved in cardiovascular diseases and may serve as a novel therapeutic target [20]. Targeting the components of PANoptosis pathways, including NOD-like receptor family pyrin domain containing 3 (NLRP3, pyroptosis), cysteine-aspartic protease 3 (caspase-3, apoptosis), and phosphorylated mixed-lineage kinase domain-like protein (p-MLKL, necroptosis), has shown promise in reducing myocardial fibrosis, inflammatory infiltration, and promoting myocardial protection in animal models of myocardial infarction (MI) [21]. Despite its importance, studies on the role of PANoptosis in the diagnosis and pathogenesis of AMI remain limited. In this study, we examined PANoptosis-related hub genes in AMI using publicly available data. Subsequently, we evaluated their diagnostic potential and correlation with peripheral immune cells, providing new insights into PANoptosis mechanisms in AMI. Materials and methods Data download and processing In this study, all data were obtained from the Gene Expression Omnibus (GEO), a public data repository that researchers can access for free to download and analyze data. The datasets GSE66360 (control, n = 50; AMI, n = 49) [22] and GSE59867 (control, n = 46; AMI, n = 111) [23] were retrieved using the keywords “acute myocardial infarction” and “Homo sapiens” from GEO. These datasets include RNA-seq data of blood samples from both AMI patients and healthy controls. The GSE66360 dataset was used as the training set, while the GSE59867 dataset served as the validation set. For both datasets, the expression matrices were annotated with probes corresponding to genes, utilizing platform files GPL570 and GPL6244, respectively. Additionally, a total of 109 genes (Table S1) associated with the PANoptosis process were collected from prior studies [24–28]. Identification of differentially expressed genes (DEGs) and enrichment analysis DEGs between AMI and controls were obtained using the “limma” package in R, with criteria set to an adjusted p-value < 0.05 and |log2FC| ≥1. Gene set enrichment analysis (GSEA) of the DEGs was performed using the “clusterProfiler” package in R, with statistical significance defined as an adjusted p-value < 0.05. Analysis of PANoptosis-related genes DEGs were intersected with the 109 PANoptosis-related genes to obtain PANoptosis-related DEGs. These genes were subsequently subjected to Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis using the DAVID database (https://david.ncifcrf.gov/), with an adjusted p-value < 0.05. To explore the interactions among PANoptosis-related DEGs, the corresponding proteins were analyzed using the STRING database (https://cn.string-db.org/), with a minimum interaction threshold of medium confidence (0.4). The interaction data were then imported into Cytoscape (v3.8.2) to construct a protein-protein interaction (PPI) network. In the PPI network, edges between nodes represent direct interactions, and nodes with a higher number of connecting edges indicate a more prominent role in the network. Construction of a diagnostic model PANoptosis-related hub genes were identified using Cytoscape and the random forest (RF) algorithm. First, highly connected nodes (genes) in the protein-protein interaction (PPI) network were analyzed using Cytoscape, employing four algorithms: maximum neighborhood component (MNC), degree, edge percolated component (EPC), and maximal clique centrality (MCC) [29]. These algorithms take into account not only the direct connections between a node and its neighbors but also its relationship with the entire network structure. The top five genes with the highest connectivity were identified as candidate hub genes. Second, the “randomForest” package in R was used to rank genes by their relative importance (default parameters: ntree = 500, mtry = floor(sqrt(p); p denotes the number of input features), with genes having a relative importance score > 10 selected as PANoptosis-related hub genes. Diagnostic models based on RF and decision tree (DT) algorithms were constructed using these hub genes. Receiver operating characteristic (ROC) curves were generated using the “pROC” package in R to evaluate the predictive accuracy of the models and the hub genes in diagnosing AMI. Construction and validation of a nomogram A nomogram based on PANoptosis-related hub genes was constructed using the “rms” package in R. Each gene was assigned a specific score, and the risk of AMI was predicted based on the cumulative scores of all included genes. The discriminatory power of the nomogram was evaluated using the area under the curve (AUC) of the ROC curve. The agreement between the predicted probabilities and the actual outcome was assessed using calibration curves. The clinical utility of the nomogram was further assessed by decision curve analysis (DCA) using the “ggDCA” package in R. GSEA of PANoptosis-related hub genes Based on the median expression value of each PANoptosis-related hub gene, AMI samples were classified into low and high expression groups. To further investigate the functions of the hub genes in AMI, GSEA was performed using the “h.all.v2023.2.Hs.symbols.gmt” gene set obtained from the MSigDB database. The analysis was conducted with the “clusterProfiler” package in R, and an adjusted p-value of < 0.05 was considered statistically significant. Correlation analysis between PANoptosis-related hub genes and AMI-related genes Genes associated with the occurrence of AMI were retrieved from the GeneCards database (https://www.genecards.org/) using the keyword “acute myocardial infarction”. Differential expression analysis of these genes was performed between AMI and control groups, with the rank-sum test used to assess the differences. The correlation between these differentially expressed AMI-related genes and PANoptosis-related hub genes was then explored using Pearson correlation analysis. These analyses aim to provide insights into the potential link between PANoptosis and AMI. Construction of transcription factor regulatory network Transcription factors that regulate the PANoptosis-related hub genes in blood were identified using the Cistrome DB database (http://cistrome.org/db), with a threshold of RP_score > 0.7. The transcription factor regulatory network was then visualized using Cytoscape software. Differences in the expression patterns of these transcription factors between control and AMI groups were assessed using the rank-sum test. Construction of lncRNA-miRNA-mRNA (competing endogenous RNA, ceRNA) regulatory network Interactions between PANoptosis-related hub genes and miRNAs were predicted using the miRWalk database (http://mirwalk.umm.uni-heidelberg.de/), retaining miRNAs predicted by at least one database. Based on these miRNAs, lncRNAs were further predicted using the DIANA-LncBase Predicted v.2 database (https://dianalab.e-ce.uth.gr/html/diana/web/index.php?r=lncbasev2), retaining lncRNAs with scores greater than 0.9 as well as those organized as blood. The lncRNA-miRNA-mRNA interactions were visualized using Cytoscape software to construct a ceRNA network. Immune microenvironment analysis ssGSEA was utilized to compare the differences in the levels of 23 immune cells between AMI and control groups. To investigate the potential relationship between PANoptosis and immune in AMI, Pearson correlation analysis was performed on PANoptosis-related hub genes and differential immune cells. Drug prediction Based on PANoptosis-related hub genes, their corresponding small molecule drugs were predicted using the Drug Signature Database (DSigDB), accessed through Enrichr (https://www.amp.pharm.mssm.edu/Enrichr/). Molecular docking was then performed to explore the potential binding between targets and drugs. The 3D structures of the drugs and targets were obtained from PubChem (https://pubchem.ncbi.nlm.nih.gov) and RCSB-PDB (http://www.rcsb.org/), respectively. The protein structures were processed using PyMOL 2.4.0 and AutoDock Tools 1.5.7 (ADT) software, where water molecules were removed, nonpolar hydrogen atoms were added, Gasteiger charges were calculated, and AD4 type was assigned. The drug structures were also processed by rotating flexible bonds and calculating Gasteiger charges. Finally, docking was performed using the genetic algorithm with AutoGrid4 and AutoDock4 programs, and the results were visualized using PLIP [30]. Real-time qPCR Blood samples from 6 healthy controls and 8 AMI patients were collected for expression verification of the hub genes. These subjects had no prior medical history of cardiovascular disease, hypertension, diabetes, or other diseases. The clinical information of the subjects is shown in Table S2. GAPDH and ACTB were used as internal reference genes, and the primer sequences are listed in Table S3. Total RNA was extracted from the blood samples using the Blood RNA Extraction Kit (Magen, China), and reverse transcription was performed using the FastQuant cDNA First Strand Synthesis Kit (TIANGEN, China). PCR was then conducted using the SuperReal PreMix Plus (SYBR Green, TIANGEN). Data analysis was performed with GraphPad Prism v10.1.2. Differences between groups were assessed using unpaired t-tests, and p < 0.05 was considered statistically significant. Results Inflammatory response and apoptotic pathways are activated in AMI To explore the differences in gene expression patterns associated with AMI, we analyzed transcriptome data from the GSE66360 dataset. A total of 438 DEGs were identified, of which 340 were upregulated and 98 were downregulated (Fig. 1A-B). GSEA revealed activation of several pathways related to inflammation and apoptosis, including “HALLMARK_INFLAMMATORY_RESPONSE”, “HALLMARK_TNFA_SIGNALING_VIA_NFKB”, and “HALLMARK_APOPTOSIS” (Fig. 1C-D). These findings suggest that inflammatory cell death may play a crucial role in the pathophysiology of AMI. Fig. 1Identification of differentially expressed genes. (A) Volcano plot showing differentially expressed genes (DEGs) between AMI and controls in the GSE66360 dataset, using a threshold of p < 0.05 and |log2FC| ≥1. (B) The heat map of DEGs. (C) Gene set enrichment analysis (GSEA) of DGEs illustrating the up-regulated pathways in AMI. (D) GSEA of DGEs illustrating the down-regulated pathways in AMI Identification of differentially expressed genes. (A) Volcano plot showing differentially expressed genes (DEGs) between AMI and controls in the GSE66360 dataset, using a threshold of p < 0.05 and |log2FC| ≥1. (B) The heat map of DEGs. (C) Gene set enrichment analysis (GSEA) of DGEs illustrating the up-regulated pathways in AMI. (D) GSEA of DGEs illustrating the down-regulated pathways in AMI Identification of genes related to PANoptosis and AMI 438 DEGs overlapped with 109 PANoptosis-related genes to obtain eight PANoptosis-related DEGs: IL1B, NLRP3, GZMB, TLR4, CD14, TNF, TNFAIP3, and GZMA (Fig. 2A). GO and KEGG analyses revealed that these genes were significantly enriched in various inflammatory pathways, such as the NF-kappa B signaling pathway and the NOD-like receptor signaling pathway, as well as pathways related to cell death, including the apoptosis and necroptosis (Fig. 2B-C). Additionally, the PPI network analysis indicated complex interactions among all eight genes (Fig. 2D-E). Fig. 2Identification of genes related to PANoptosis and AMI. (A) The intersection of 438 DEGs with 109 PANoptosis-related genes. (B) GO analyses illustrating relevant biological processes (BP) and cellular components (CC). (C) KEGG enrichment analysis. (D) The PPI network of eight PANoptosis-related DEGs. (E) Visualize the target network of PANoptosis-related DEGs, where node size and color depth represent the degree value Identification of genes related to PANoptosis and AMI. (A) The intersection of 438 DEGs with 109 PANoptosis-related genes. (B) GO analyses illustrating relevant biological processes (BP) and cellular components (CC). (C) KEGG enrichment analysis. (D) The PPI network of eight PANoptosis-related DEGs. (E) Visualize the target network of PANoptosis-related DEGs, where node size and color depth represent the degree value Identification of IL1B and NLRP3 as PANoptosis-related hub genes in AMI through PPI and machine learning The CytoHubba algorithm was utilized to evaluate the importance of genes in the PPI network. Five key genes were initially identified using four algorithms within the CytoHubba plugin, MNC, Degree, EPC, and MCC (Fig. 3A). Further analysis with the RF algorithm identified IL1B and NLRP3 as PANoptosis-related hub genes (Fig. 3B-C). Fig. 3Identification of IL1B and NLRP3 as PANoptosis-related hub genes in AMI. (A) Identification of hub genes by four PPI algorithms. (B-C) Identification of hub genes by random forest (RF) method. (B) The error rate of RF. (C) Genes were ranked by relative importance, with a relative importance score > 10 selected as PANoptosis-related hub genes. (D) Sixteen of the 206 genes linked to AMI occurrence, as identified from the GeneCards database, were significantly differentially expressed when comparing AMI to controls. (E) Pearson correlation analysis showing that IL1B and NLRP3 significantly correlated with 16 AMI occurrence-related genes. (F) In all AMI occurrence-related genes, IL1B was most strongly correlated with IL1RN, and (G) NLRP3 was most strongly correlated with IL1B Identification of IL1B and NLRP3 as PANoptosis-related hub genes in AMI. (A) Identification of hub genes by four PPI algorithms. (B-C) Identification of hub genes by random forest (RF) method. (B) The error rate of RF. (C) Genes were ranked by relative importance, with a relative importance score > 10 selected as PANoptosis-related hub genes. (D) Sixteen of the 206 genes linked to AMI occurrence, as identified from the GeneCards database, were significantly differentially expressed when comparing AMI to controls. (E) Pearson correlation analysis showing that IL1B and NLRP3 significantly correlated with 16 AMI occurrence-related genes. (F) In all AMI occurrence-related genes, IL1B was most strongly correlated with IL1RN, and (G) NLRP3 was most strongly correlated with IL1B Validation of IL1B and NLRP3 in AMI occurrence A total of 206 genes associated with the occurrence of AMI, each with a relevance score > 30, were retrieved from the GeneCards database. Differential expression analysis revealed that 16 of these genes showed significant expression differences between AMI and control groups, including IL1B and NLRP3 (Fig. 3D). This suggests a potential association between these two genes and AMI. Furthermore, IL1B and NLRP3 exhibited significant positive correlations with other AMI-related genes (Fig. 3E). IL1B demonstrated the strongest correlation with IL1RN (R = 0.84, p < 2.2E-16), while NLRP3 was most strongly correlated with IL1B (R = 0.8, p < 2.2E-16) (Fig. 3F-G). These findings suggest that the two PANoptosis-related hub genes may not only play pivotal roles in AMI development but also function in a closely related manner. IL1B and NLRP3 exhibit diagnostic value in AMI The diagnostic potential of IL1B and NLRP3 for AMI was assessed using ROC curves. The AUC values for IL1B and NLRP3 were 0.881 and 0.847, respectively (Fig. 4A). Further, diagnostic models based on these two hub genes were constructed using RF and DT algorithms. The AUC values of the RF and DT models were 0.900 and 0.916, respectively (Fig. 4B). These results indicate that IL1B and NLRP3 could effectively diagnose AMI, and their combined use enhances diagnostic accuracy. Validation of these results in the GSE59867 dataset demonstrated consistent results, with AUC values for IL1B, NLRP3, RF, and DT all close to or above 0.7 (Fig. 4C-D). Fig. 4Construction and validation of diagnostic models and a nomogram. (A) The ROC curves of PANoptosis-related hub genes (IL1B and NLRP3) in the GSE66360 dataset. (B) The ROC curves of diagnostic models (RF and DT) in the GSE66360 dataset. (C) The ROC curves of PANoptosis-related hub genes in the GSE59867 dataset. (D) The ROC curves of diagnostic models in the GSE59867 dataset. (E) A nomogram was established to visualize the predictive power of IL1B and NLRP3 for AMI diagnosis in the GSE66360 dataset. (F) A calibration curve was generated to demonstrate the alignment between the nomogram’s predicted probabilities and actual outcomes. (G) The ROC curves of the nomogram. (H) A decision curve analysis (DCA) was performed to show the superior clinical benefit of the nomogram. (I) A nomogram was established in the GSE59867 dataset. (J) Calibration curve. (K) ROC curve. (L) DCA analysis Construction and validation of diagnostic models and a nomogram. (A) The ROC curves of PANoptosis-related hub genes (IL1B and NLRP3) in the GSE66360 dataset. (B) The ROC curves of diagnostic models (RF and DT) in the GSE66360 dataset. (C) The ROC curves of PANoptosis-related hub genes in the GSE59867 dataset. (D) The ROC curves of diagnostic models in the GSE59867 dataset. (E) A nomogram was established to visualize the predictive power of IL1B and NLRP3 for AMI diagnosis in the GSE66360 dataset. (F) A calibration curve was generated to demonstrate the alignment between the nomogram’s predicted probabilities and actual outcomes. (G) The ROC curves of the nomogram. (H) A decision curve analysis (DCA) was performed to show the superior clinical benefit of the nomogram. (I) A nomogram was established in the GSE59867 dataset. (J) Calibration curve. (K) ROC curve. (L) DCA analysis A nomogram was subsequently constructed using IL1B and NLRP3 to predict the risk of AMI prevalence (Fig. 4E). Calibration curves demonstrated good predictive performance of the nomogram (Fig. 4F). The AUC value of the nomogram was 0.911, underscoring its accuracy in estimating AMI risk (Fig. 4G). DCA further confirmed the nomogram’s clinical utility, showing a benefit for patient outcomes (Fig. 4H). Similar validation results were observed in the GSE59867 dataset, where the nomogram achieved an AUC value of 0.848 (Fig. 4I-L). Taken together, these findings reveal the diagnostic value of IL1B and NLRP3 as potential PANoptosis-related biomarkers for AMI. Moreover, the better accuracy of the nomogram based on these two genes suggests its promising application in clinical settings for AMI diagnosis and risk assessment. Potential molecular mechanisms associated with IL1B and NLRP3 To explore the biological pathways related to IL1B and NLRP3 in AMI, we performed GSEA analyses. The results showed that “HALLMARK_IL6_JAK_STAT3_SIGNALING”, “HALLMARK_INFLAMMATORY_RESPONSE”, “HALLMARK_TGF_BETA_SIGNALING” and “HALLMARK_TNFA_SIGNALING_VIA_NFKB” pathways were all significantly enriched in the IL1B and NLPR3 high expression groups (Fig. 5A-B). These results suggest that IL1B and NLRP3 may play a key role in the onset and development of AMI through related pathways, including inflammatory response and apoptosis. Fig. 5Gene set enrichment analysis and transcription factors regulatory network. (A) The GSEA showing pathways related to high expression of IL1B in AMI. (B) The GSEA showing pathways related to high expression of NLRP3 in AMI. (C) Transcription factors regulatory network illustrating upstream regulatory factors of IL1B and NLRP3. Black boxes indicate significant differences in transcription factor expression between AMI and controls. (D) A lncRNA-miRNA-mRNA regulatory network. MiRNAs showing an opposite expression trend to IL1B in AMI and lncRNAs displaying a similar expression trend to IL1B Gene set enrichment analysis and transcription factors regulatory network. (A) The GSEA showing pathways related to high expression of IL1B in AMI. (B) The GSEA showing pathways related to high expression of NLRP3 in AMI. (C) Transcription factors regulatory network illustrating upstream regulatory factors of IL1B and NLRP3. Black boxes indicate significant differences in transcription factor expression between AMI and controls. (D) A lncRNA-miRNA-mRNA regulatory network. MiRNAs showing an opposite expression trend to IL1B in AMI and lncRNAs displaying a similar expression trend to IL1B To explore their upstream regulatory mechanisms, we predicted the transcription factors of these hub genes using the Cistrome DB database. A total of 11 transcription factors were identified as potential regulators of IL1B and NLRP3 (Fig. 5C). Notably, CEBPB and SPI1 were found to be co-regulators of both hub genes, with their expression showing significant differences between AMI and controls. In the miRWalk database, it is predicted that IL1B interacts with hsa-miR-328-3p, hsa-miR-4743-3p, hsa-miR-6090, and hsa-miR-24-3p, while NLRP3 interacts with hsa-miR-548b-5p (Figure S1). Based on these five miRNAs, 244 lncRNAs were predicted in the DIANA - LncBase Predicted v.2 database. Considering the negative regulatory relationships between lncRNAs, miRNAs, and mRNAs, three pairs of interactions were identified, including IL1B-has-miR-646-LINC00936/LINC01094/AC144652.1 (Fig. 5D). IL1B and NLRP3 are associated with immune cells in AMI To investigate the differences in the immune microenvironment between AMI and controls, we compared the abundance of 23 immune cell types in the GSE66360 dataset. The results indicated that the levels of 18 immune cell types were significantly different between the AMI and control groups (Fig. 6A). With the exception of activated B cells, the remaining immune cells showed significant correlations with IL1B and NLRP3 (Fig. 6B). Of these, IL1B had a strong correlation with mast cells (R = 0.820, p = 2.94E-25), neutrophils (R = 0.804, p = 1.34E-23), activated dendritic cells (R = 0.799, p = 3.61E-23), and macrophages (R = 0.792, p = 1.75E-22), while NLRP3 showed a strong correlation with macrophages (R = 0.720, p = 4.34E-17). These findings suggest that these PANoptosis-related hub genes may influence the progression of AMI by regulating immune cells. Fig. 6Immune microenvironment analysis. (A) A box plot showing a comparative analysis of the abundance of 23 immune cell types between AMI and controls in the GSE66360 dataset. (B) Correlation analysis of differential immune cells with IL1B and NLRP3 Immune microenvironment analysis. (A) A box plot showing a comparative analysis of the abundance of 23 immune cell types between AMI and controls in the GSE66360 dataset. (B) Correlation analysis of differential immune cells with IL1B and NLRP3 Drug prediction Based on combined scores, the top five potential candidate drugs associated with IL1B and NLRP3 were identified in the DSigDB database. These drugs are antimicrobial agents such as triclocarban (combined score: 523540.03, p = 2.03E-6) and chlorhexidine (combined score: 495164.71, p = 4.10E-6), as well as compounds like uric acid (combined score: 495164.71, p = 4.10E-6), GNF-Pf-4325 (combined score: 491266.61, p = 4.51E-6), and 9-methoxyellipticine (combined score: 489385.26, p = 4.73E-6), which has anticancer properties. These drugs may help regulate infection and disease-related survival pathways by targeting IL1B and NLRP3. We subsequently investigated their binding potential through molecular docking (Fig. 7). Both the drugs and their targets bind spontaneously without the need for external energy, and a binding energy of less than − 6 kcal/mol indicates a strong interaction [31]. Of these compounds, chlorhexidine showed the highest binding affinity for IL1B (-6.01 kcal/mol) and NLRP3 (-4.90 kcal/mol). Fig. 7Drug prediction and molecular docking. Molecular docking models of IL1B (RCSB PDB: 8RYS) and NLRP3 (RCSB PDB: 3QF2) with triclocarban (PubChem ID: 7547), chlorhexidine (PubChem ID: 9552079), GNF-Pf-4325 (PubChem ID: 2199), and 9-methoxyellipticine (PubChem ID: 72512) Drug prediction and molecular docking. Molecular docking models of IL1B (RCSB PDB: 8RYS) and NLRP3 (RCSB PDB: 3QF2) with triclocarban (PubChem ID: 7547), chlorhexidine (PubChem ID: 9552079), GNF-Pf-4325 (PubChem ID: 2199), and 9-methoxyellipticine (PubChem ID: 72512) Validation of the expression of IL1B and NLRP3 Compared to controls, the expression levels of IL1B and NLRP3 were increased in the AMI group in the GSE66360 dataset (Fig. 8A). Consistent expression patterns were observed in the GSE59867 dataset (Fig. 8B). Moreover, real-time qPCR results also showed the increased expression levels of IL1B and NLRP3 in the AMI group (Fig. 8C). Fig. 8Validation of the expression of IL1B and NLRP3. (A) The differences in IL1B and NLRP3 in AMI and control samples in the GSE66360 dataset. (B) The differences in IL1B and NLRP3 in AMI and control samples in the GSE59867 dataset. (C) The expression levels of IL1B and NLRP3 in AMI and control samples were measured using real-time qPCR Validation of the expression of IL1B and NLRP3. (A) The differences in IL1B and NLRP3 in AMI and control samples in the GSE66360 dataset. (B) The differences in IL1B and NLRP3 in AMI and control samples in the GSE59867 dataset. (C) The expression levels of IL1B and NLRP3 in AMI and control samples were measured using real-time qPCR Discussion Cardiomyocyte loss through apoptosis is a major contributor to myocardial injury and dysfunction in AMI, further driving fibrosis and heart failure development [32]. Extensive crosstalk has been observed between pyroptosis, apoptosis, and necroptosis [33]. PANoptosis, a novel inflammatory PCD mechanism, involves the formation of the PANoptosome complex and simultaneous activation of all three PCD pathways to mediate cell death [34]. Simultaneous inhibition of necroptosis and apoptosis has demonstrated greater cardioprotection against myocardial ischemia-reperfusion injury (MIRI, which refers to the exacerbation of heart damage following reperfusion during AMI treatment) than targeting either pathway alone [35]. PANoptosis plays a regulatory role in myocardial injury after MI [21]. In our study, DEGs between AMI and controls were enriched in inflammatory, immune, and apoptotic pathways, indicating that PANoptosis may contribute to AMI pathogenesis. While current research on AMI diagnostic markers primarily focuses on apoptosis and necroptosis [36, 37], the link between PANoptosis and AMI remains unexplored. We employed bioinformatics tools to identify PANoptosis-related diagnostic markers in AMI, explore their molecular mechanisms, and analyze their correlation with immune cells. In the AMI dataset, IL1B and NLRP3 were identified as PANoptosis-related hub genes significantly linked to AMI occurrence. NLRP3, an innate immune receptor activated by DAMPs, pathogens, or homeostatic imbalances, recruits caspase-1 through adaptor protein ASC (apoptosis-associated speck-like protein containing a CARD), leading to inflammasome assembly and activation [38]. This process triggers the release of pro-inflammatory factors such as interleukin (IL)-1β (encoded by IL1B) and IL-18, inducing cell death [39]. Recent research has emphasized that the NLRP3 inflammasome is part of the PANoptosome complex, which works with other inflammasome receptors to promote PANoptosis [40]. During MIRI, PANoptosome components like NLRP3 are activated in myocardial tissue, mediating PANoptosis [41]. IL-1β and tumor necrosis factor (TNF)-α, elevated due to chronic inflammation in aortic aneurysms, could activate Z-DNA binding protein 1 (ZBP1) and absent in melanoma 2 (AIM2), which ultimately trigger PANoptosis in vascular smooth muscle cells [42]. In AMI, increased expression of IL1B and NLRP3 has been observed in cardiac fibroblasts [43]. and anti-IL-1β treatments reduce collagen accumulation and fibrosis in infarcted areas [44]. The NLRP3/IL-1β/caspase-1 pathway has also been implicated in AMI rats, modulating inflammation, apoptosis, and myocardial injury [45]. Overall, IL1B and NLRP3 may be key regulators of the PANoptosis pathway in AMI. Additionally, IL1B and NLRP3 showed diagnostic potential for AMI, both in the diagnostic model and in the nomogram. Previous research has reported that IL1B levels in venous blood are positively correlated with classical inflammatory markers and moderately associated with cardiac functional parameters such as the wall motion score index, left ventricular ejection fraction (LVEF), and stroke volume (SV) in patients with ST-segment elevation myocardial infarction (STEMI), suggesting its potential value in evaluating myocardial injury and adverse remodeling risk [46]. In addition, NLRP3 may have the potential to serve as a complementary marker for inflammatory phenotype assessment in STEMI patients with chronic kidney disease [46]. Therefore, these genes may be regarded as potential PANoptosis-related markers that may provide complementary information on inflammatory phenotypes and assist in the accurate diagnosis and personalized treatment of AMI. It is well known that inflammatory and immune pathways are among the important pathological processes in AMI. Our analysis showed that most of the immune cells were dysregulated in AMI, echoing previous studies [47, 48]. Notably, IL1B and NLRP3 were significantly associated with dysregulated immune cells, such as macrophages, mast cells, activated dendritic cells, and neutrophils, suggesting a potential immunomodulatory role. NLRP3 inflammasomes in macrophages can be activated by L5-low density lipoprotein, promoting IL-1β production and influencing inflammatory response in AMI [49]. Mast cells are involved in both the onset and resolution of inflammation, particularly in regulating post-infarction fibrosis [50, 51], which can be modulated by NLRP3 [52]. Rapid infiltration of neutrophils into cardiac tissue during AMI allows for increased severity of cardiac injury [53]. This process is mediated by granulopoiesis induced by the NLRP3-IL-1β signaling axis in neutrophils within the bone marrow [54]. Conversely, during the repair phase, CD4+ T cells infiltrate the infarcted area to promote angiogenesis and scar formation [55]. Interestingly, we observed a negative correlation between PANoptosis-related genes and CD4+ T cells. All these studies confirmed our results. Previous studies have shown that PANoptosis regulates macrophage and neutrophil function, thereby affecting the disease state [56, 57]. Therefore, IL1B and NLRP3 may play a significant role in the interaction between PANoptosis and immune cells, regulating the inflammatory response, immune activity, and repair processes in AMI. We also explored the upstream and downstream regulatory relationships of IL1B and NLRP3 to reveal potential molecular mechanisms. GSVA results showed the association of IL1B and NLRP3 with signaling pathways such as JAK/STAT3, IFN, TNF-β, and TNFα/NFκB in AMI, supporting prior evidence [49, 58]. Transcription factors CEBPB and SPI1 were identified as common regulators of these hub genes and were differentially expressed in AMI. It has been shown that CEBPB (encoding CCAAT/enhancer binding protein beta, C/EBPβ) is a key factor in the inflammatory response of monocytes and is associated with cardiac development and repair [59, 60]. SPI1 (encoding ETS-domain transcription factor, PU.1) is a key regulator of a variety of immune cells, and its activation could exacerbate cardiac tissue damage and MI development [61]. In atherosclerosis, CEBPB mediates NLRP3 transcription, attenuating macrophage pyroptosis [62], suggesting that it may have a similar role in AMI. Furthermore, we identified has-miR-646 potentially targeting IL1B and predicted 3 lncRNAs associated with them. These regulatory relationships have not been confirmed in previous studies. Overall, these analyses reveal a complex regulatory relationship between IL1B and NLRP3 in AMI, which remains to be validated by in vivo and in vitro studies. Potential drugs targeting IL1B and NLRP3 were identified, including chlorhexidine. Chlorhexidine is widely used as an antimicrobial agent in wound and periodontal therapy. Clinical trials have demonstrated that periodontal therapy incorporating chlorhexidine can affect cardiovascular disease markers [63]. Additionally, it could induce apoptosis to necrosis in macrophages in vitro [64], revealing its potential to modulate multiple cell death pathways. Although chlorhexidine showed potential binding affinity with the identified hub proteins in the molecular docking analysis, its clinical applicability for AMI remains highly limited. In the cardiovascular field, chlorhexidine is mainly used for infection prevention in patients with cardiac implantable electronic devices [65]. Furthermore, chlorhexidine is primarily used as a topical antiseptic and has been reported to exert cytotoxic effects that may affect cellular function and tissue morphology [66, 67]. Toxicokinetic studies in rats indicate that chlorhexidine is rapidly absorbed and distributed but eliminated relatively slowly (t1/2 = 8.92 h), suggesting a potential risk of accumulation after repeated administration, with major distribution in plasma and kidney tissues [68]. Therefore, its potential application in AMI requires extreme caution and further investigation regarding its possible modes of use. Although our findings provide novel insights into the potential role of PANoptosis in AMI, this study has several limitations. We primarily explored PANoptosis-related mechanisms in AMI through bioinformatics analysis, identified hub genes, and assessed their diagnostic value, as well as their associations with immune infiltration and transcriptional regulation. However, further in vivo and in vitro experiments are required to validate the biological roles of hub genes and pathways. Moreover, while IL1B and NLRP3 demonstrated consistent diagnostic value across the training set, validation set, and RT-qPCR, the clinical sample size used for experimental validation was relatively small. This size is insufficient to provide statistically robust validation for a diagnostic model. Thus, their diagnostic utility still needs to be confirmed in larger, well-designed prospective cohorts. Finally, although we identified PANoptosis-related genes associated with AMI, PANoptosis is defined by the assembly of the PANoptosome complex and activation of key executioner proteins. Therefore, mRNA expression alone cannot confirm the actual occurrence of PANoptosis. Future studies incorporating in vitro and in vivo experiments are required to validate these findings and further elucidate the mechanistic role of PANoptosis in AMI. Conclusion In this preliminary pilot exploration, we identified two PANoptosis-associated hub genes, IL1B and NLRP3, that may serve as potential diagnostic biomarkers to assist in the evaluation of AMI. Our findings indicate the dysregulation of immune cells in AMI and their correlation with these hub genes, highlighting the intricate interactions between PANoptosis and immune responses in AMI pathogenesis. We also proposed that CEBPB and SPI1 may play a crucial role as common regulators of these hub genes in PANoptosis. Overall, our study provides preliminary insights into the possible involvement of PANoptosis in AMI development and may offer a basis for future investigations into diagnostic biomarkers and therapeutic targets. Supplementary Information Supplementary Material 1 Supplementary Material 1